Aptorum Group Limited (NASDAQ:APM) Sees Significant Drop in Short Interest

Aptorum Group Limited (NASDAQ:APM) was the recipient of a significant decline in short interest during the month of January. As of January 15th, there was short interest totaling 1,025 shares, a decline of 61.8% from the December 31st total of 2,681 shares. Based on an average daily volume of 50,669 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are sold short. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 50,669 shares, the short-interest ratio is presently 0.0 days.

Aptorum Group Price Performance

Shares of NASDAQ:APM opened at $0.81 on Friday. The company’s fifty day moving average is $1.15 and its two-hundred day moving average is $1.51. Aptorum Group has a 12-month low of $0.69 and a 12-month high of $4.47.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Aptorum Group in a research note on Monday, December 22nd. Wall Street Zen raised Aptorum Group from a “sell” rating to a “hold” rating in a research note on Saturday, October 11th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Aptorum Group currently has a consensus rating of “Sell”.

About Aptorum Group

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.